Berlin – Germany, 2024-02-23

Milestone in Cannabis Regulation: The Cannabis Act (CanG) has been approved

The Ampel Coalition fulfilled the promise from the November 2021 coalition agreement by passing the CanG in the Bundestag on February 23, 2024.

The bill was first discussed in the Bundestag in October of last year, and since then, several adjustments have been made to the original draft. The law, passed in the second and third readings, is set to come into effect on April 1, 2024. It will allow the use of cannabis either through personal cultivation or as part of membership in a cultivation association. The cultivation associations are expected to become active from July 1, 2024, onwards.

The changes introduced by the CanG are scheduled for initial evaluation in 2025, with further evaluations planned at specific intervals.

The passage of the CanG in the Bundestag on February 23, 2024, marks a significant milestone on the path to the legalization of cannabis in Germany. This step constitutes the first part of a two-pillar plan developed by the federal government for its legalization initiative. The second pillar of the plan will involve a temporary pilot project, establishing specialized cannabis stores for the controlled distribution of cannabis for recreational use.

However, the implementation of the legislative initiative may still face delays, depending on the further actions of the Bundesrat, which is expected to provide its position on the CanG on March 22, 2024. While the Bundesrat cannot prevent the passage of the law by the Bundestag, it may engage the mediation committee to review the law.

PR-Contact for Natural Pharma

Dr. Daniel König
+49 (0) 2173 940 95 91

About Natural Pharma

Natural Pharma Resource (Natural Pharma) GmbH was founded at the beginning of 2022 and is based in Langenfeld, Germany.

The pharmaceutical and biotechnological company focuses on the import, storage, manufacturing, distribution and export of pharmaceutical products, preparations and substances, in particular medicinal products under the German Medicines Act (AMG), narcotics under the German Narcotics Act (BtMG) and cannabis for medicinal purposes as well as research and development in this field.

We are licensed pharmaceutical wholesalers according to § 52a of the German Medicines Act (AMG) and have a permit to handle narcotics according to § 3 of the Federal Institute for Drugs and Medical Devices (BtMG).

For more information, visit: Natural Pharma

Our Philosophie

The company philosophy of Natural Pharma is simple. The goal is to provide patients with high quality natural and medicinal products, especially those made from cannabis plants.
Natural Pharma Resource GmbH is committed to selecting manufacturers that take into account important patient welfare criteria in order to provide an additional therapeutic option for patients with previously unsatisfactory therapeutic outcomes.
The company’s own products, partner products and also targeted products of German competitors will be offered via the Natural Pharma sales platform.

Business partner

Become our partner and actively participate with your resources in the German cannabis market. With our in-depth understanding of the German cannabis market and our extensive experience in natural pharma, we provide you with a secure and profitable investment opportunity.

Internal forwarding: Press “Partnership” button please